Long-Term Treatment of Insomnia with Zolpidem: A Multicentre General Practitioner Study of 107 Patients
The DOI matches its Crossref record.
Abstract
The effects of Zolpidem, an imidazopyridine derivative, were studied in 107 patients suffering from insomnia, 60.9% of whom were over 60 years of age, in a 6-month, single-blind, flexible dose, general practitioner study. Comparison was made between baseline, last day of treatment and 10 days after the end of treatment to assess efficacy and rebound insomnia. An improvement in all efficacy parameters – time taken to fall asleep, total amount of nocturnal sleep and number of nocturnal awakenings – was reported by the investigator and the patients; the improvement was evident from the first evaluation day and was maintained throughout the trial. Improvement was also maintained during the washout period with a lack of rebound insomnia. There was no sign of withdrawal symptoms and tolerance to Zolpidem did not develop over the 6-month treatment period. Adverse events were mild and infrequent, and tended to resolve with a dose reduction. It is concluded that 10 mg/day Zolpidem is an appropriate starting dose and is effective and safe for the treatment of sleep disturbances of different origins. Les effets du Zolpidem, un dérivé des 1'imidazopyridines, ont été évalués chez 107 patients insomniaques dont 60,9% étaient âgés de plus de 60 ans. Le Zolpidem a été administré en simple aveugle pendant 6 mois, à des doses variables, par des médecins généralistes. L'évaluation a été effectuée en comparant 1'état initial du patient, à celui observé au dernier jour du traitement et 10 jours après son interruption brutale. Une amélioration de tous les paramètres d'efficacité – temps d'endormissement, durée totale de sommeil et nombre de réveils nocturnes – a été observée tant par les investigateurs que par les patients; elle a été evidente dés le premier jour d'évaluation et s'est maintenue tout au long de l'étude. L'amélioration s'est maintenue après 1'arrêt du traitement, sans que l'on n'observe de rebond d'in-somnie; et aucun phénomène de tolérance au Zolpidem n'a été observé au cours des 6 mois de traitement. Aucun symptôme de sevrage n'a été observé a l'arrêt du traitement. Les effets secondaires ont été peu fréquents et de faible intensité, et ont tendu à disparaître lors d'une rêduction de la dose. On peut conclure de cette étude que la dose de 10 mg de Zolpidem par jour représente une dose initiate adéquate, efficace, et bien tolérée, dans les troubles du sommeil d'origines diverses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Comparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia
Smith, M. T., Perlis, M. L., Park, A., Smith, M. S., Pennington, J., Giles, D. E., & Buysse, D. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.5 · Cited by 863
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Wilt, T. J., MacDonald, R., Brasure, M., Olson, C. M., Carlyle, M., Fuchs, E., Khawaja, I. S., Diem, S., Koffel, E., Ouellette, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1781 · Cited by 275
Behavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
Metadata
- Authors
- Schlich, D., L'Heritier, C., Coquelin, J. P., & Attali, P.
- Venue
- Journal of International Medical Research
- Publisher
- SAGE Publications
- Published
- 1991-05
- Volume
- 19
- Issue
- 3
- Pages
- 271-279
- ISSN
- 0300-0605 (ISSN-L)
- 1473-2300
- OpenAlex
- W2162698906
- Cited by
- 80
- References
- 0
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Treatment of Insomnia with Zolpidem: A Multicentre General Practitioner Study of 107 Patients. https://app.cochat.ai/papers/10.1177/030006059101900313
- The paper
- Schlich, D., L'Heritier, C., Coquelin, J. P., & Attali, P. (1991). Long-Term Treatment of Insomnia with Zolpidem: A Multicentre General Practitioner Study of 107 Patients. Journal of International Medical Research. https://doi.org/10.1177/030006059101900313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.